ICON Plc Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of ICON Plc Insights data

Headline Published Journalists
Showing 3 of 100+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 08 Mar 2022 Lorem
Rational Vaccines in CRO talks for Phase I/II therapeutic herpes vaccine trial, ICON is ‘frontrunner’; eyes USD 30–60m Series B by 3Q22 28 Jan 2022 William Newton
Vaxart engaged with CRO Icon for Phase II trial of COVID-19 vaccine tablet 11 Nov 2021 Reynald Castaneda
DreamTec teams up with CROs ICON and WuXi Clinical for Phase I oral COVID-19 vaccine trial eyed for 1Q22 05 Nov 2021 Reynald Castaneda
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer